# Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma

> **NCT05092217** · PHASE2 · UNKNOWN · sponsor: **Eye & ENT Hospital of Fudan University** · enrollment: 80 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Tirelizumab
- **PROCEDURE:** salvage surgery

## Key facts

- **NCT ID:** NCT05092217
- **Lead sponsor:** Eye & ENT Hospital of Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-20
- **Primary completion:** 2023-10-20
- **Final completion:** 2024-10-20
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2021-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05092217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05092217, "Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05092217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*